Tobramycin inhalation solution - Novartis
Alternative Names: TOBI; TOBI NextGen; TOBI® solution; Tobramycin aerosol - ChironLatest Information Update: 23 Dec 2021
Price :
$50 *
At a glance
- Originator Novartis
- Class Aminoglycosides; Anti-infectives; Antibacterials; Antibronchitics; Small molecules
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cystic fibrosis-associated respiratory tract infections
- No development reported Ventilator associated pneumonia
- Discontinued Bronchiectasis; Respiratory tract infections; Tuberculosis
Most Recent Events
- 20 Sep 2019 No development reported - Phase-II for Ventilator-associated-pneumonia in Germany (Inhalation)
- 31 Aug 2018 Tobramycin inhalation solution market licensed to Mylan worldwide
- 31 Jul 2017 Discontinued - Phase-III for Cystic fibrosis-associated respiratory tract infections (In infants, In children) in Romania, Egypt, Poland, Italy, Germany, Greece, France, Russia, Switzerland, Hungary and Canada (Inhalation), because not listed on Novartis pipeline, December 2016